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Summary This cohort study was conducted amongst female patients manifesting lipoatro-
phy while receiving stavudine-containing ﬁrst-line antiretroviral treatment regimens at two
urban health centres in Rwanda. The objectives were to assess weight evolution after stavu-
dine substitution and to describe any signiﬁcant difference in weight evolution when zidovudine
or tenofovir/abacavir was used for substitution. All adult patients on stavudine-containing
ﬁrst-line regimens who developed lipoatrophy (diagnosed using a lipodystrophy case deﬁni-
tion study-based questionnaire) and whose treatment regimen was changed were included
(n = 114). In the most severe cases stavudine was replaced with tenofovir or abacavir (n = 39),
and in the remainder with zidovudine (n = 75). For patients changed to zidovudine a progres-
sive weight loss was seen, while those on tenofovir/abacavir showed a progressive weight
increase from six months. The between-group difference in weight evolution was signiﬁcant
from nine months (difference at 12 months: 2.3 kg, P = 0.02). These differences were conﬁrmed
by follow-up lipoatrophy scores. In multivariate analysis, substitution with tenofovir/abacavir
remained signiﬁcantly associated with weight gain. This is the ﬁrst study in Africa assessing
weight gain as a proxy for recovery after stavudine substitution due to lipoatrophy, provid-
ing supporting evidence that tenofovir/abacavir is superior to zidovudine. The weight lossPlease cite this article in press as: van Griensven J,
in Rwanda after stavudine substitution due to lipoatrophy: co
Soc Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.08.015
with zidovudine might justify e
fovir/abacavir.
© 2008 Royal Society of Tropica
reserved.
∗ Corresponding author. Tel.: +250 08 597623; fax: +250 08 510993.
E-mail address: jvgrie@yahoo.com (J. van Griensven).
0035-9203/$ — see front matter © 2008 Royal Society of Tropical Medicin
doi:10.1016/j.trstmh.2008.08.015et al. Weight evolution in HIV-1 infected women
mparison of zidovudine with tenofovir/abacavir. Trans R
arlier substitution and access to better alternatives like teno-
l Medicine and Hygiene. Published by Elsevier Ltd. All rights
e and Hygiene. Published by Elsevier Ltd. All rights reserved.
 INT
2
1
B
p
a
p
t
b
o
(
i
l
t
i
i
r
a
t
s
t
h
s
o
m
p
W
(
s
t
c
w
l
r
n
s
w
o
l
t
a
p
t
l
h
t
h
p
h
Z
d
l
a
m
i
o
a
t
s
i
2
2
T
l
c
u
c
T
i
W
o
r
e
c
H
s
r
p
2
P
l
b
w
p
m
s
i
2
P
o
l
v
c
g
i
b
t
o
o
c
e
I
t
f
AARTICLE+ModelRSTMH-989; No. of Pages 7
. Introduction
ody fat changes, commonly referred to as lipodystro-
hy, occur frequently in HIV-1 infected patients on highly
ctive antiretroviral treatment (HAART). Lipodystrophy can
resent as subcutaneous fat loss, including hollowing of
he cheeks, wasting of extremities or ﬂattening of the
uttocks (lipoatrophy), or relative/absolute accumulation
f central/visceral fat in the abdomen, neck or breasts
lipohypertrophy).1 Whereas lipohypertrophy can present
ndependently of HIV and HAART,2,3 lipoatrophy is clearly
inked with HAART, especially stavudine, and is more likely
o improve upon treatment change.4
Due to the frequent occurrence of side-effects, includ-
ng lipoatrophy, stavudine is no longer a ﬁrst-choice drug
n high-income countries.1,4 Although several papers have
eported on the relatively high prevalence of lipoatrophy
nd other complications, such as symptomatic hyperlac-
ataemia/lactic acidosis (SH/LA) linked to the use of
tavudine in Africa,4—6 its use in Africa is likely to con-
inue for some years to come for various reasons.7 The WHO
as recently recommended a dose-reduction strategy for
tavudine in the hope that this will signiﬁcantly reduce the
ccurrence of these long-term side-effects without compro-
ising treatment efﬁcacy. However, the effectiveness of this
lan is yet to be determined.8
Based on studies from high-income countries, current
HO guidelines recommend substitution with abacavir
ABV) or tenofovir (TDF) when lipoatrophy occurs while on
tavudine-containing regimens.8 In low-income countries,
he high cost and limited availability of TDF and ABV pre-
lude their being widely used, and in these contexts patients
ill often be changed to zidovudine (ZDV). Although cumu-
ative toxicity is less pronounced with ZDV, it still exists,
endering such a strategy a temporary measure. What is
ot known is how, once lipoatrophy has developed, sub-
titution with ZDV compares to TDF/ABV. This is important
hen considering how long resource-poor contexts can rely
n ZDV.6
One of the challenges of performing studies addressing
ipoatrophy in Africa is the lack of technical measurements
o conﬁrm the ﬁndings. Instead, we rely on questionnaires
nd clinical assessments that, despite being simple, have
erformed well in comparative studies.4 We note that lipoa-
rophy has been shown to be associated with (recent) weight
oss.9—14
Medecins Sans Frontières (MSF) has been supporting two
ealth centres in Rwanda since 2003. Due to the fact that
his support programme has had access to TDF and ABV we
ave been in the unique position of being able to follow
atients who were switched to either ZDV or TDF/ABV. There
as been only one study in the literature that used both
DV and ABV for stavudine replacement,15 but it did not
irectly compare the efﬁcacy of the drugs and we would
ike to report on our experience.
We previously reported a high level of lipoatrophy
mongst patients on stavudine-containing ﬁrst-line regi-Please cite this article in press as: van Griensven J,
in Rwanda after stavudine substitution due to lipoatrophy: co
Soc Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.08.015
ens within our antiretroviral treatment (ART) programme
n Rwanda, using a standardized questionnaire.14 Based
n this population, the objectives of this study were to
ssess weight evolution after stavudine substitution and
o describe the differences in weight evolution following
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tavudine replacement by ZDV and TDF/ABV in patients man-
festing lipoatrophy while receiving ﬁrst-line ART regimens.
. Methods
.1. Design and setting
his was an observational cohort study using routinely col-
ected data from a programmatic setting. The study was
onducted between October 2003 and July 2007 in two
rban public health centres (Kimironko and Kinyinya health
entres) in Kigali, Rwanda that were supported by MSF.16
he two centres have over 3000 patients on ART, which
s offered according to WHO eligibility criteria and using
HO-recommended ﬁrst-line regimens.8 Approximately 90%
f this cohort was started on generic ﬁxed-dose combination
egimens containing stavudine, lamivudine and nevirapine.
General measures were provided in the ART facility to
nsure patient conﬁdentiality, consent for HIV testing, and
ounselling and support for those who received a positive
IV test result. All patients were counselled on the potential
ide-effects of ART and were managed for these by expe-
ienced clinicians. Conﬁdentiality was maintained with no
atient identiﬁers used.
.2. Inclusion criteria
atients were routinely screened for stavudine-related
ipoatrophy using a lipodystrophy case deﬁnition study-
ased questionnaire (see below). At the same time, patients
ere evaluated for symptoms suggestive of SH/LA. All adult
atients on stavudine-containing ﬁrst-line regimens for a
inimum uninterrupted duration of six months and for whom
tavudine had been substituted due to lipoatrophy were
ncluded in this study.
.3. Exclusion criteria
atients diagnosed with severe SH/LA (serum lactate level
f ≥5mmol/l [Accutrend Lactate; Roche, Basel, Switzer-
and] or a serum lactate level of ≥2.5mmol/l with profuse
omiting or with a respiratory rate >20/min) with asso-
iated features of lipoatrophy were excluded, since they
enerally required different clinical management includ-
ng treatment interruption. Since weight can be affected
y various conditions, strict exclusion criteria were applied
o reduce misclassiﬁcation and improve the speciﬁcity of
ur assessment. Particular attention was given to ruling
ut opportunistic infections, especially tuberculosis. Every
ase of suspected lipoatrophy was carefully examined by an
xperienced physician and underwent appropriate testing.
f necessary, patients were referred to the university hospi-
al (Centre Hospitalière Universitaire de Kigali, Rwanda) for
urther investigation (bronchoscopy, ultrasound, X-ray, etc).
ll cases with concurrent infections were excluded. Duringet al. Weight evolution in HIV-1 infected women
mparison of zidovudine with tenofovir/abacavir. Trans R
ach follow-up visit patients were re-assessed for subclin-
cal infections and, if conﬁrmed, they were excluded from
he analysis.
All patients in the programme had a viral load test
one after one year of therapy. In addition, patients with
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Weight evolution after stavudine substitution
immunological or clinical signs suggestive of treatment
failure8 had a viral load test performed; those with a viral
load >1000 copies/ml were excluded.
For every patient with a clinical suspicion of lipoatrophy,
poor nutritional intake was explored as an alternative expla-
nation for the body changes.17,18 The dietary intake over
the last 3—6 months was assessed and the social situation
was evaluated by the social assistant or nurse. If nutrition-
related fat loss seemed plausible, nutritional support was
provided for 1—2 months. Those with clinical improvement
upon nutritional support were excluded from the analy-
sis. None of the patients included in this study received
or required further nutritional support after stavudine sub-
stitution. The study excluded the only two eligible male
patients so as to obtain a homogeneous population of female
patients.
2.4. Assessment and management of lipoatrophy
Lipoatrophy was assessed using a lipodystrophy case deﬁni-
tion study-based questionnaire as described previously.14,19
In brief, this method combines self-reporting along with
a formal clinical assessment by the healthcare provider,
and was routinely performed on all adult patients who had
been on stable ﬁrst-line ART for over one year. This method
has been shown to correlate well with dual energy X-ray
absorptiometry (DEXA) measurements.20 Fat loss occurring
in any of seven body regions (face, neck, arms, breasts,
abdomen, buttocks and legs) was systematically assessed.
The degree of lipoatrophy at each region was rated using
the HIV Outpatient Study (HOPS) scale as follows: absent
(score of 0), mild (noticeable on close inspection, score
of 1), moderate (readily noticeable by patient or physi-
cian, score of 2) or severe (readily noticeable to a casual
observer, score of 3). The impact of body habitus on the ﬁt of
patients’ clothing was also noted. A total lipoatrophy score
was obtained by adding the scores for each body region. A
clinical protocol reﬂecting the consensus on the manage-
ment of lipoatrophy among treating physicians within the
programme was developed to decide on whether to sub-
stitute with TDF or AZT, with the aim of reserving TDF for
the more severe cases. Stavudine substitution was indicated
for those with a total lipoatrophy score >5, which we con-
sidered to be clinically signiﬁcant. TDF (or ABV when TDF
was not available) was given to all patients with a high
total lipoatrophy score (>10) or with a rapid clinical evo-
lution and associated (non-severe) SH/LA. The remainder
were given AZT. Although this assignment was arbitrary,
the criteria had face value and addressed our clinical con-
text. Plus, they were applied consistently to all eligible
patients.
The weight evolution at 3, 6, 9 and 12 months after stavu-
dine substitution was recorded. Weight, not body mass index
(BMI), was chosen as the main outcome for the following
reasons: ﬁrst, this study involved only adults whose height
did not change, i.e. was a constant variable, and was onlyPlease cite this article in press as: van Griensven J,
in Rwanda after stavudine substitution due to lipoatrophy: co
Soc Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.08.015
measured at baseline. In addition, the data analysis was
restricted to female patients and thus BMI variation between
genders was not an issue. Finally, in practice in busy ART
clinics, the parameter that is routinely measured on follow-
up visits to judge clinical evolution is weight and not BMI.
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owever, we did measure BMI at the beginning of treatment
nd report on its evolution in the results.
Weighing scales (Seca, Hamburg, Germany) were pro-
ided and regularly checked/calibrated by the MSF logistics
epartment. Training on the use and maintenance of the
cales was integrated into the HIV care training sessions.
atients were weighed early in the morning before the con-
ultations, without shoes and with minimal clothing. The
ame weighing scale was used for all patients. Height was
easured on admission with the patient standing upright
nd looking straight ahead.
.5. Statistics
ata analysis used Stata 9 (Stata Corp., College Station, TX,
SA). Differences between groups were compared using the
ilcoxon rank-sum test for continuous variables, the X2 test
or categorical variables and Fisher’s exact test if numbers
ere small. The Wilcoxon signed-rank test was used to assess
ithin-group differences. Multivariate linear regression was
sed to determine the independent association of drug for
ubstitution with change in weight after stavudine substitu-
ion. The weight at nine months after substitution was used
s the dependent variable, since this was the longest dura-
ion of weight data that was available for all patients (given
he differences in follow-up time after substitution). Due to
ollinearity with the main exposure, the lipoatrophy score
as not added in the multivariate model (type of drug for
ubstitution based on score). The level of signiﬁcance was
et at P < 0.05.
. Results
total of 164 patients had a substitution for stavudine;
8 were excluded as they had other concurrent conditions
long with lipoatrophy, e.g. treatment failure, malnutri-
ion, opportunistic infections or severe SH/LA, and two
ale patients were excluded to ensure a cohort of females
nly. A total of 114 women were thus included in the
tudy and were followed up for a median period of 342
ays. The characteristics of patients in whom stavudine
as substituted by ZDV (n = 75) or TDF/ABV (n = 39) are
hown in Table 1. Most patients had a relatively high BMI,
ad been on stavudine-containing regimens for over 16
onths and experienced a median body weight loss of
kg. The median CD4 count prior to lipoatrophy-related
tavudine replacement was 293 cells/l, reﬂecting good
mmunological recovery. For a minority, SH/LA was a sec-
ndary diagnosis. Seventy-ﬁve patients were switched to
DV, and 39 to TDF (n = 27) or ABV (n = 12). Patients
ho had been changed to ZDV had lower lipoatrophy
cores, had a shorter follow-up period after substitution
nd were less likely to have a secondary diagnosis of
H/LA.
Weight evolution after stavudine substitution is shown in
able 2. For patients changed to ZDV, a progressive weightet al. Weight evolution in HIV-1 infected women
mparison of zidovudine with tenofovir/abacavir. Trans R
oss was seen that became statistically signiﬁcant three
onths after substitution, with a mean loss by 12 months of
.62 kg (P < 0.01). By contrast, those on TDF/ABV maintained
stable body weight, with a trend towards a progressive
ncrease in weight after an initial period of three months.
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Table 1 Baseline characteristics of patients with lipoatrophy prior to substitution for stavudine
Baseline characteristic Total (n = 114) TDF/ABV (n = 39) ZDV (n = 75) P-value
Age (years)a 35.7 (32.3—38.4) 37.0 (34.0—39.9) 34.6 (31.9—38.1) 0.06
WHO clinical stage at baseline (n) (%)
Stage 1 1 (0.9) 0 1 (1.3) 0.47
Stage 2 13 (11.4) 3 (7.7) 10 (13.3) 0.37
Stage 3 83 (72.8) 31 (79.5) 52 (69.4) 0.25
Stage 4 17 (14.9) 5 (12.8) 12 (16.0) 0.65
CD4 count before substitution (cells/l)a,b 293 (196—370) 286 (222—367) 293 (191—375) 0.82
Time on ART (days)a 492 (404—632) 513 (392—597) 489 (404—672) 0.89
NNRTI (n) (%)
NVP 94 (82.5) 35 (89.7) 59 (78.7) 0.51
EFV 20 (17.5) 4 (10.3) 16 (21.3) 0.19
Body weight at time of substitution (kg)a 60 (53—67) 61 (53—72) 60 (52—65) 0.57
Body mass index at time of substitution (kg/m2)a 23.0 (20.9—25.5) 23.4 (21.2—26.0) 23.0 (20.7—25.4) 0.47
Total lipoatrophy scorea,c 8 (7—11) 12 (11—13) 7 (6—8) <0.01
Body weight loss prior to substitution (kg)a 3.0 (2.0—5.3) 3.3 (2.1—6.0) 3.0 (1.1—5.3) 0.39
Rate of weight loss (g/week)a 171 (93—261) 158 (101—304) 181 (80—250) 0.33
Secondary diagnosis of SH/LA (n) (%)
No 100 (87.7) 30 (76.9) 70 (93.3) 0.40
Yes 14 (12.3) 9 (23.1) 5 (6.7) 0.02
Length of follow-up after substitution (days)a 342 (252—436) 398 (261—507) 337 (241—400) 0.03
TDF: tenofovir; ABV: abacavir; ZDV: zidovudine; ART: antiretroviral treatment; NNRTI: non-nucleoside reverse transcriptase inhibitors;
NVP: nevirapine; EFV: efavirenz; SH/LA: symptomatic hyperlactataemia/lactic acidosis.
a Median (interquartile range).
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9b In the 6 months prior to substitution; missing for ﬁve individual
c Obtained by adding the HIV Outpatient Study lipoatrophy score
ate = 2; severe = 3.
signiﬁcant difference in weight evolution between the
wo treatment groups was seen from nine months (Table 2).
he corresponding difference in BMI between both groups
as 0.65 kg/m2 (95% CI 0.09—1.20) and 0.89 kg/m2 (95% CI
.13—1.64) at 9 and 12 months, respectively.
Since allocation to ZDV or TDF/ABV was based on clinical
arameters, we performed a multivariate analysis to assess
hether the observed differences in weight remained valid
fter adjusting for various clinical parameters (Table 3).
fter adjustment for potential confounders, the association
f TDF/ABV with weight recovery remained signiﬁcant. The
ndings did not change substantially when BMI evolution wasPlease cite this article in press as: van Griensven J,
in Rwanda after stavudine substitution due to lipoatrophy: co
Soc Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.08.015
ncluded as the outcome variable (between-group differ-
nce in BMI evolution of 0.95 kg/m2 by nine months after
ubstitution).
w
a
2
Table 2 Evolution of body weight after substitution for stavudine
Time since substitution (months) Mean (SD) change over time
TDF/ABV ZDV
3 −0.17 (1.60) −0.57 (1.
6 +0.01 (2.49) −1.24 (3.
9 +0.25 (2.82) −1.41 (4.
12 +0.70 (4.18) −1.62 (4.
TDF: tenofovir; ABV: abacavir; ZDV: zidovudine.
a P-value <0.05 in signed-rank test (within-group difference).each region of the body: lipoatrophy absent = 0; mild = 1; moder-
To assess the extent to which the difference in weight
volution correlated with differences in the clinical evo-
ution, we compared follow-up lipoatrophy scores in both
roups at 6—9 months after substitution. Results were avail-
ble for 63 (84%) of those changed to ZDV and for 34 (87%)
f those changed to TDF/ABV. For those on ZDV, the median
ipoatrophy score decreased signiﬁcantly (−2 [IQR −3 to
1], P < 0.01), while the increase seen with TDF/ABV was
ot statistically signiﬁcant (+1 [0 to +2], P = 0.06). How-
ver, the between-group difference in scores at 6—9 months
fter substitution was highly signiﬁcant (P < 0.01). For the
2 individuals with complete data, TDF/ABV was associatedet al. Weight evolution in HIV-1 infected women
mparison of zidovudine with tenofovir/abacavir. Trans R
ith a more favourable score evolution in the multivari-
te analysis (mean between-group difference in score of
.4).
(n = 114)
(kg) Mean (95% CI) between-group
difference (kg)
P-value
75)a 0.40 (−0.27; 1.07) 0.24
59)a 1.25 (−0.02; 2.52) 0.05
11)a 1.66 (0.20; 3.11) 0.03
23)a 2.32 (0.36; 4.27) 0.02
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Table 3 Multivariate analysis to assess the independent association of type of drug substitution with weight change (kg)a
Baseline variables Bivariate analysis Multivariate analysis
Coefﬁcient P-value Coefﬁcient P-value
NRTI (ZDV vs. TDF/ABV) −1.787 0.02 −2.413 <0.01
Time on ART (days) 0.003 0.18 0.001 0.51
Age (years) −0.036 0.53 −0.021 0.70
WHO clinical stage (1/2 vs. 3/4) −0.257 0.82 −1.500 0.14
CD4 count before substitution (cells/l) −0.002 0.42 −0.003 0.18
NNRTI (EFV vs. NVP) −0.778 0.42 −0.863 0.32
Body weight at time of substitution (kg) −0.085 0.02 −0.069 0.07
Body weight loss prior to substitution (kg) 0.287 <0.01 0.439 <0.01
Rate of weight loss (g/week) −0.003 0.18 0.004 0.20
Secondary diagnosis of SH/LA −2.461 0.02 −2.586 0.02
NRTI: nucleoside reverse transcriptase inhibitor; ZDV: zidovudine; TDF: tenofovir; ABV: abacavir; ART: antiretroviral treatment; NNRTI:
P: ne
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a Excluding ﬁve individuals with missing CD4 data (n = 109).
4. Discussion
This is the ﬁrst study in Africa assessing weight evolution
after the substitution of stavudine due to lipoatrophy. Sub-
stituting with TDF/ABV was associated with weight gain,
while substituting with ZDV led to a progressive weight loss
over time. This difference in weight evolution between the
two groups was signiﬁcant from six months after stavudine
substitution. Similar differences in follow-up lipoatrophy
scores were found. We note that the two cohorts were not
randomly selected, but that the TDF/ABV group had more
severe symptoms and hence this difference is clinically more
signiﬁcant.
The positive clinical evolution after substituting TDF or
ABV for stavudine was consistent with three studies from
high-income countries (including two randomised controlled
trials), demonstrating a slow and partial reversal of fat
loss.15,21,22 Only one uncontrolled study addressed the efﬁ-
cacy of substituting stavudine with ZDV or ABV.15 In that
study, some fat recovery was observed with ZDV although
less pronounced than with ABV. This was in contrast to
the ﬁndings in the current study, which we speculate were
due to differences in clinical status at presentation, sever-
ity/duration of lipoatrophy and the differences in outcome
measurements.
One of the possible limitations of this study was that we
used self-reporting, clinical assessment and, in particular,
‘weight evolution’ as an indicator of fat recovery after sub-
stitution. However, for health facilities in resource-limited
settings that are faced with high patient burdens, shortages
of staff (both in terms of numbers and capacity) and lack
of sophisticated technical investigations, measurement of
body weight is a relevant and easy-to-use parameter for the
follow-up of patients on ART, as it can indicate important
clinical events such as treatment failure, malnutrition and
infections.23Please cite this article in press as: van Griensven J,
in Rwanda after stavudine substitution due to lipoatrophy: co
Soc Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.08.015
Lipoatrophy should also be considered when unexplained
weight loss is encountered, in particular for patients on ART
for longer periods and/or for those on stavudine-containing
regimens. In contrast to the weight loss/wasting syndrome
associated with progressive HIV infection, lipoatrophy is
w
c
s
tvirapine; SH/LA: symptomatic hyperlactataemia/lactic acidosis.
istinguished by the preferential loss of fat tissue with-
ut substantial loss of lean tissue mass, and has most
ommonly been documented in patients responding well
o therapy.1 In a prospective evaluation, body weight was
hown to increase throughout the ﬁrst year of successful
tavudine- or ZDV-containing ART, resulting from increased
entral fat, peripheral fat and lean body mass. However,
elective peripheral fat loss associated with body weight
eduction was observed after longer treatment periods.11
number of other studies have conﬁrmed the association
f lipoatrophy with (recent) weight loss.9—14 In any case,
nexplained weight loss calls for thorough clinical and lab-
ratory investigations. In settings with limited resources,
ipoatrophy is essentially a diagnosis of exclusion, retained
s an explanation for (subcutaneous) fat loss after alterna-
ive explanations have been ruled out.
The response to treatment can provide additional diag-
ostic evidence. Weight loss associated with malnutrition
ends to resolve readily with nutritional support, something
hat has been progressively more available within many ART
rogrammes in poor countries.17 Upon successful virolog-
cal suppression or treatment of opportunistic infections,
ody weight generally recovers quickly.24,25 After stavu-
ine substitution, the peripheral fat loss can gradually be
eversed, although this occurs slowly and is probably not
ully reversible.15,21,22 By contrast, associated lipohypertro-
hy seems to be unaffected by stavudine substitution.15,21,22
ecent studies have documented the association of lipoa-
rophy and weight after stavudine substitution.13,26 Body
eight evolution after substitution could thus provide a
seful (albeit insensitive) clinical indicator of fat recovery.
lthough the lipoatrophy follow-up scores were in line with
he weight evolution in our study, anthropometric measure-
ents such as waist circumference and skin-fold thickness
ight have allowed us to correlate the weight changes with
egional changes in body fat. Unfortunately, this informationet al. Weight evolution in HIV-1 infected women
mparison of zidovudine with tenofovir/abacavir. Trans R
as not available in our study as it came from a routinely-
ollected data set, but this should be considered in further
tudies.
Another limitation of this assessment was the limited
echnical investigations available to validate the clinical
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iagnosis of lipoatrophy or to rule out mimicking conditions.
lthough there is a theoretical possibility that some patients
ight have had sub-clinical infections that would have
ffected weight, we think this was minimised by screening
atients for infections on a routine basis at each follow-up
isit; all were given instructions to return in case of feeling
nwell. Tuberculosis, in particular, might pass undiagnosed
nd is a reason for weight loss; however, this is unlikely as all
atients were on ART for extended periods, and the result-
ng restoration in immune function would have facilitated
he diagnosis of tuberculosis early in the treatment pro-
ess. Still, our observations need to be conﬁrmed in other,
ore controlled settings. Additionally, long-term outcomes
emain to be ascertained, and repeated lipoatrophy score
ssessments, metabolic data and patient self-reporting after
ubstitution might have corroborated our ﬁndings. How-
ver, our observations indicate the need to explore further
his important operational question in low-income coun-
ries.
The more favourable response to TDF/ABV than to ZDV
dds to the evidence that TDF/ABV is superior to ZDV as
n alternative to stavudine. This highlights the need for
mproved access to TDF/ABV and suggests that pro-active,
arlier substitution with TDF/ABV might be justiﬁed. This
s because, although lipoatrophy is not life-threatening,
he potential repercussions of ART-related body changes on
dherence to and overall acceptability of ART have to be
onsidered.27
There are a number of areas that merit further research.
or example, it would be useful to correlate the clinical
nd weight assessments with more technical investigations
uch as bioelectrical impedance analysis; assessments could
e conducted on larger cohorts in different contexts from
urs; and ﬁnally, assessments in resource-limited settings
till using stavudine in ﬁrst-line ART regimens could look at
hen to substitute for stavudine.
Meanwhile, these data provide additional support for the
rgent need for increased availability of TDF or ABV for
RT programmes in low-income countries. As lipoatrophy is
frequent complication of stavudine-containing regimens
nd is only partially reversible upon substitution, preventive
trategies including earlier detection and substitution for
tavudine with drugs such as TDF/ABV need to be explored.
elying on ZDV should only be a stop-gap measure until that
ime.
uthors’ contributions: JVG conceived the study; JVG and
FA were physicians treating the patients within the ART
rogramme and implemented the study; JVG, RZ, FR and
R were involved with the study design and performed the
ata analysis; JVG and RZ co-drafted the manuscript; EA,
R and TR critically reviewed the manuscript and improved
he intellectual content. All authors read and approved the
nal manuscript. JVG is guarantor of the paper.
cknowledgements: We are grateful to all the staff ofPlease cite this article in press as: van Griensven J,
in Rwanda after stavudine substitution due to lipoatrophy: co
Soc Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.08.015
he Kimironko and Kininya health centres for their work
n HIV/AIDS and to the Ministry of Health of Rwanda for
heir excellent collaboration. We are particularly grateful
o all the patients who participated in this assessment.
his HIV/AIDS programme was supported by Médecins Sans PRESS
J. van Griensven et al.
rontières and ran in collaboration with the Rwandan
inistry of Health.
unding: The MSF project received funding from the Euro-
ean Union, the Belgian Development Cooperation (DGCD)
nd the Global Fund to ﬁght AIDS, Tuberculosis and Malaria.
onﬂicts of interest: None declared.
thical approval: The data included in this analysis con-
tituted part of routine programmatic data collected for
onitoring and evaluation purposes carried out in collabo-
ation with the Ministry of Health of Rwanda. The Rwandan
ational Ethics Committee (RNEC, Kigali, Rwanda) gave
xemption from formal ethical review.
eferences
1. Grinspoon R, Carr A. Cardiovascular risk and body-fat
abnormalities in HIV-infected patients. N Engl J Med
2005;352:48—62.
2. Study of Fat Redistribution and Metabolic Change in HIV Infec-
tion (FRAM). Fat distribution in women with HIV infection. J
Acquir Immune Deﬁc Syndr 2006;42:562—71.
3. Justman JE, Hoover DR, Shi Q, Tan T, Anastos K, Tien PC, et
al. Longitudinal anthropometric patterns among HIV-infected
and HIV-uninfected women. J Acquir Immune Deﬁc Syndr
2008;47:312—9.
4. Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds
D, et al. Current concepts in the diagnosis and management of
metabolic complications of HIV infection and its therapy. Clin
Infect Dis 2006;43:645—53.
5. Boulle A, Orrell C, Kaplan R, Van Cutsem G, McNally M, Hilder-
brand K, et al. Substitutions due to antiretroviral toxicity or
contraindication in the ﬁrst 3 years of antiretroviral treatment
in a large South African cohort. Antivir Ther 2007;12:753—60.
6. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT.
Antiretroviral therapy-associated toxicities in the resource-
poor world: the challenge of a limited formulary. J Infect Dis
2007;196:S449—56.
7. WHO. Report on WHO/UNAIDS meeting on forecasting
ARV needs up to 2010. 7—8 November 2005. Geneva:
World Health Organization; 2005. www.who.int/hiv/amds/
ReportForecastingMeeting.pdf [accessed 21 July 2008].
8. WHO. Antiretroviral treatment for HIV infection in adults and
adolescents in resource-limited settings: towards universal
access. Recommendations for a public health approach.
2006 Revision. Geneva: World Health Organization; 2006.
http://www.who.int/hiv/pub/guidelines/adult/en/index.html
[accessed 21 July 2008].
9. Carr A, Miller J, Law M, Cooper DA. A syndrome of
lipoatrophy, lactic acidaemia and liver dysfunction associ-
ated with HIV nucleoside analogue therapy: contribution
to protease inhibitor-related lipodystrophy syndrome. AIDS
2000;14:25—32.
10. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B,
Palella FJ, et al. Clinical assessment of HIV-associated lipodys-
trophy in an ambulatory population. AIDS 2001;27:1389—98.
11. Mallon P, Miller J, Cooper DA, Carr A. Prospective evaluation
of the effects of antiretroviral therapy on body composition inet al. Weight evolution in HIV-1 infected women
mparison of zidovudine with tenofovir/abacavir. Trans R
HIV-1-infected men starting therapy. AIDS 2003;17:971—9.
12. Brown TT, Chu H, Wang Z, Palella FJ, Kingsley L, Witt MD, et al.
Longitudinal increases in waist circumference are associated
with HIV-serostatus, independent of antiretroviral therapy.
AIDS 2007;21:1731—8.
 INARTICLE+ModelTRSTMH-989; No. of Pages 7
Weight evolution after stavudine substitution
13. Tien PC, Schneider MF, Cole SR, Justman JE, French AL, Young
M, et al. Relation of stavudine discontinuation to anthropomet-
ric changes among HIV-infected women. J Acquir Immune Deﬁc
Syndr 2007;44:43—8.
14. van Griensven J, De Naeyer L, Mushi T, Ubarijoro S,
Gashumba D, Gazille C, et al. High prevalence of lipoatrophy
among patients on stavudine-containing ﬁrst-line antiretrovi-
ral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg
2007;101:793—8.
15. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit
P, Lonergan JT, et al. Improvement in lipoatrophy associated
with highly active antiretroviral therapy in human immunod-
eﬁciency virus-infected patients switched from stavudine to
abacavir or zidovudine: the results of the TARHEEL study. Clin
Infect Dis 2004;38:263—70.
16. Médecins Sans Frontières. Antiretroviral therapy in pri-
mary healthcare: Scaling-up in two health centres in
Kigali, Rwanda. Brussels: Médecins Sans Frontières; 2007.
http://www.msf.org/source/countries/africa/rwanda/2007/
MSF Rwanda%20capitalisation ﬁnal.pdf [accessed 21 July
2008].
17. Gerrior JL, Neff LM. Nutrition assessment in HIV infection. Nutr
Clin Care 2005;8:6—15.
18. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP,
Kumarasamy N. Adverse effects of highly active antiretro-
viral therapy in developing countries. Clin Infect Dis
2007;15:1093—101.Please cite this article in press as: van Griensven J,
in Rwanda after stavudine substitution due to lipoatrophy: co
Soc Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.08.015
19. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An
objective case deﬁnition in HIV-infected adults: a case-control
study. Lancet 2003;361:726—35.
20. McComsey G, Riordan M, Storer N, Goldman S, Ganz J, Libutti D,
et al. Clinical lipoatrophy assessment strongly correlates with PRESS
7
DEXA-measured limb fat and subcutaneous fat mitochondrial
DNA levels. In: 13th Conference on Retroviruses and Oppor-
tunistic Infections; 5-8 February 2006; Denver. Abstract 751.
http://www.retroconference.org/2006/Abstracts/26736.HTM
[accessed 21 July 2008].
21. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et
al. Reversibility of lipoatrophy in HIV-infected patients 2 years
after switching from a thymidine analogue to abacavir: the
MITOX Extension Study. AIDS 2004;18:1029—36.
22. Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E,
Churchill D, et al. A randomized comparative trial of teno-
fovir DF or abacavir as replacement for a thymidine analogue
in persons with lipoatrophy. AIDS 2006;20:2043—50.
23. Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and
HIV infection: review of weight loss and wasting in the era
of highly active antiretroviral therapy from the nutrition for
healthy living cohort. Clin Infect Dis 2006;42:836—42.
24. Kennedy N, Ramsay A, Uiso L, Gutmann J, Ngowi FI, Gillespie
SH. Nutritional status and weight gain in patients with pul-
monary tuberculosis in Tanzania. Trans R Soc Trop Med Hyg
1996;90:162—6.
25. Wools-Kaloustiana K, Kimaiyo S, Diero L, Siika A, Sidle J, Yian-
noutsos CT, et al. Viability and effectiveness of large-scale HIV
treatment initiatives in sub-Saharan Africa: experience from
western Kenya. AIDS 2006;20:41—8.
26. Ananworanich J, Nuesch R, Côté HC, Kerr SJ, Hill A, Jupimai
T, et al. Changes in metabolic toxicity after switching fromet al. Weight evolution in HIV-1 infected women
mparison of zidovudine with tenofovir/abacavir. Trans R
stavudine/didanosine to tenofovir/lamivudine–a Staccato trial
substudy. J Antimicrob Chemother 2008;61:1340—3.
27. Mutimura E, Stewart A, Crowther NJ. Assessment of quality
of life in HAART-treated HIV-positive subjects with body fat
redistribution in Rwanda. AIDS Res Ther 2007;4:19.
